PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35342408-0	2022	microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/p27 Signaling Pathway in Hepatocellular Carcinoma.	Sorafenib	73-82	cyclin-dependent kinase inhibitor 1B	Mus musculus	112-115	
35342408-9	2022	Altogether, these data suggest that miR-106b-5p promotes cell proliferation and cell cycle and increases HCC cells" resistance to sorafenib through the BTG3/Bcl-xL/p27 signaling pathway.	Sorafenib	130-139	cyclin-dependent kinase inhibitor 1B	Mus musculus	164-167	
24852430-6	2014	Notably, Tiam1 siRNA or sorafenib alone obviously increased p27 level, but reduced Mcl-1 and bcl-2 levels in xenografted nude mice, and their combinations reached the best effect.	Sorafenib	24-33	cyclin-dependent kinase inhibitor 1B	Mus musculus	60-63	
21693435-7	2011	Inhibition of Raf kinases with either sorafenib or B-Raf small interfering RNA (siRNA) caused a mitogen-activated protein kinase-mediated downregulation of p27.	Sorafenib	38-47	cyclin-dependent kinase inhibitor 1B	Mus musculus	156-159	
21693435-9	2011	Finally, theophylline-mediated increases in p27 and cyclin D1 were attenuated by sorafenib, which modulated Raf/MEK/ERK signaling.	Sorafenib	81-90	cyclin-dependent kinase inhibitor 1B	Mus musculus	44-47